Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.28 USD
+0.05 (4.07%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum C VGM
Fundamental Charts
About Return on Equity (TTM)
Pacific Biosciences of California, Inc.'s return on equity, or ROE, is -66.75% compared to the ROE of the Medical - Instruments industry of -13.99%. While this shows that PACB has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
PACB 1.28 +0.05(4.07%)
Will PACB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio Stock Up on Q2 Earnings & Revenue Beat Estimates, Margin Rises
Pacific Biosciences (PACB) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Pacific Biosciences of California (PACB) Reports Q2 Loss, Beats Revenue Estimates
Other News for PACB
Sideways movement on September 17 results in no shift to PACB’s technical outlook
Technical picture remains unchanged for PACB after it rises 2.5% on September 16
Technical picture remains unchanged for PACB after it rises 2.56% on September 15
PACB falls 7.14% on September 12, leaving the technical picture intact
The technical outlook for PACB is unchanged after it rises 3.28% on September 11